Nearly two-thirds of breast cancer patients are diagnosed with advanced disease in China

ATLANTA - July 7, 2016 - PRLog -- Renub Research has announced the addition of the "http://www.renub.com/china-molecular-diagnostics-market-test-volume-and-forecast-491-p.php" report to its offering

After Cardiovascular disease Cancer is the second-most important reason of casualty in China. In China there is a general trend toward patient presentation with later stages of cancer. This trend is especially noticeable in breast and prostate cancer. Nearly two-thirds of breast cancer patients are diagnosed with advanced disease in China. Delayed diagnosis can be attributable to lack of accessible screening programs and limited understanding of the importance of early detection in China. However, Government cancer screening programs, NGOs and companies initiatives are motivating them for early diagnosis.

Reader will get to know the following data from the report

•    China Molecular Oncology Test Market Share (2010 - 2019)

•    Oncology Testing Market (2010 - 2019)

•    Breast Cancer Testing Market (2010 - 2019)

•    Colorectal Cancer Testing Market (2010 - 2019)

•    Prostate Cancer Testing Market (2010 - 2019)

Click here to view the report details: http://www.renub.com/china-molecular-diagnostics-market-t...

For more information:

Contact Us

Rajat Gupta

Sr. Manager

Sales & Marketing Div

Renub Research

Email: info@renub.com

Phone:  +1-678-302-0700 (USA), +91-120-421-9822, +91-120-424-9780 (India)

Web: http://www.renub.com

Follow us:

https://www.facebook.com/RenubResearch/

https://twitter.com/renubresearch

https://www.linkedin.com/company/renub-research

https://plus.google.com/+renubresearch

https://www.youtube.com/c/renubresearch